In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Array BioPharma Inc.. Trade Record

NASDAQ:ARRY Array BioPharma Inc. stock gains 22.27% Exit Jun 18, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart ARRY May 10, 2018, priceSeries
About Array BioPharma Inc.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, and Selumetinib for the treatment of cancer, as well as ASC08/Danoprevir, a protease inhibitor for hepatitis C virus. Its drug candidates in Phase II clinical trials comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASLAN001/Varlitinib, a pan-HER2 inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; Prexasertib/LY2606368, a chk-1 inhibitor for cancer; LOXO-101, a PanTrk inhibitor for cancer; and ONT-380/ARRY-380, an HER2 inhibitor for breast cancer. The company's Phase I drugs include GDC-0994, an ERK inhibitor for cancer; and ARRY-382, a CSF1R inhibitor for cancer, as well as Phase Ib drug candidate comprises GDC-0575, a chk-1 inhibitor for cancer. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.

Trade Information
Trade Type
LONG
ReliabilityScore™
96.18
Entry Date
May 10, 2018
Entry Price
14.44
Sell Date
Jun 18, 2018
Sell Price
17.66
Net Gain
22.27%
Hold Time
26 Trading Days